Back to search

Boston University

Pharmacoepidemiological studies of treatments for chronic inflammatory skin diseases

Abstract

dc:description.abstract

The rapid expansion of new immunomodulatory therapies for inflammatory skin diseases has intensified the need for timely, rigorous real-world safety evidence. While administrative claims data are a valuable source for generating rapid post-marketing evidence, pharmacoepidemiologic studies relying on these data face persistent methodological challenges, including limited sample sizes for newly approved therapies, unmeasured confounding by disease severity, and complex treatment patterns that complicate causal inference. This dissertation addresses these challenges through three interconnected aims that span study design methodology, bias quantification, and applied comparative safety research in psoriasis and atopic dermatitis.In the first aim, we compared the risk of infections and malignancy among patients with psoriasis initiating interleukin-17 inhibitors (IL-17i) versus tumor necrosis factor inhibitors (TNFi) using three pharmacoepidemiologic study designs: an active-comparator new user design, a hierarchical prevalent new user design, and a switcher new user design. No significant differences in serious infection, outpatient infection, or malignancy were observed across the three designs. The hierarchical prevalent new user design provided improved precision during the early post-approval years while yielding point estimates similar to the traditional new user design, supporting its use as a complementary approach for early post-marketing surveillance when new user sample sizes are limited. The second aim employed a simulation-based quantitative bias analysis calibrated to the three Aim 1 cohorts to quantify the expected residual bias from unmeasured disease severity and to evaluate the effectiveness of proxy adjustment of unmeasured disease severity, such as use of non-biologic immunomodulatory medications at baseline. The proxy-confounder correlation emerged as the primary determinant of bias reduction, achieving up to 48% reduction in bias due to unmeasured disease severity at a proxy-confounder correlation of 0.7 but negligible improvement at 0.2. Under the most clinically plausible scenario, residual bias of 13–25% on the odds ratio scale persisted after proxy adjustment, providing practical benchmarks for interpreting claims-based comparative safety estimates that lack clinical severity data. The simulations also revealed that standard propensity score adjustment can occasionally increase bias through bias unmasking when measured and unmeasured confounders exert opposing effects. The third aim applied these methodological insights to a comparative safety study of Janus kinase (JAK) inhibitors versus Th2 cytokine inhibitors among adults with atopic dermatitis, in relation to the risk of skin and soft tissue infections. JAK inhibitor use was associated with a 78% increased hazard of skin and soft tissue infections (HR = 1.78; 95% CI: 1.43–2.23), compared to Th2 cytokine inhibitors, with the excess risk emerging after 60 days of treatment. Young adults, males, and patients with greater baseline treatment burden were at highest risk. Marginal structural models with time-varying inverse probability of treatment weighting yielded a modestly higher estimate (HR = 1.98), suggesting that time-varying confounders partially masked the association. Collectively, this dissertation contributes to methodological considerations in the design, analysis, and interpretation of claims-based comparative safety studies of immunomodulatory therapies for chronic inflammatory skin diseases and provides real-world evidence on the infection risk profile of JAK inhibitors in atopic dermatitis that may inform clinical monitoring strategies.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Epidemiology
Grantor
Boston University
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Jin, Yinzhu
Advisor dc:contributor.advisor
  • Jick, Susan S.
ORCID dc:identifier.orcid

Subjects

dc:subject × 2

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/52942

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Jin, Yinzhu. Pharmacoepidemiological studies of treatments for chronic inflammatory skin diseases. doctoral thesis, Boston University, 2026. https://hdl.handle.net/2144/52942